This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The massive and unrestricted use of human immunodeficiency virus 1 (HIV-1) protease inhibitors (PIs) began in Spain in the last 3 months of 1996, although some patients had already been treated with ritonavir through expanded access programs.¹ The introduction of PIs, and consequently of highly active antiretroviral therapy, has been associated with a dramatic change in the natural history of HIV-1 infection.^2-3 A huge decrease in acquired immunodeficiency syndrome (AIDS)–defining events, the need for hospital admission, and AIDS-associated mortality has been attributed to the introduction of highly active antiretroviral therapy.^2-3 Moreover, the quality of life of HIV-infected patients has improved substantially since the widespread use of highly active antiretroviral therapy.¹ However, PIs have many important adverse effects and most times their adverse-effect profile is the most important factor limiting the efficacy of PI-based therapeutic regimens.

We have recently analyzed the clinical experience with PI antiretroviral therapy in our AIDS unit . . . [Full Text of this Article]

RELATED ARTICLE

Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter, Margaret A. Fischl, Scott M. Hammer, Martin S. Hirsch, Donna M. Jacobsen, David A. Katzenstein, Julio S. G. Montaner, Douglas D. Richman, Michael S. Saag, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, Patrick G. Yeni, and Paul A. Volberding
JAMA. 1998;280(1):78-86.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age
Sanders et al.
ANN INTERN MED 2008;148:889-903.
ABSTRACT | FULL TEXT  

The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men
Zaric et al.
Med Decis Making 2008;28:359-376.
ABSTRACT  

Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy
Sanders et al.
NEJM 2005;352:570-585.
ABSTRACT | FULL TEXT  

Virologic Response Associated With a Change in Protease Inhibitor Therapy
Butcher et al.
Arch Intern Med 2000;160:394-395.
FULL TEXT